Cardiff Oncology, Inc.
Cardiff Oncology, Inc. scores highest on Torque (50) and lowest on Price (24). Its PosiPenta is 37.19 out of 100, weaker than most similar companies.
On the Penta Grid this week, Cardiff Oncology, Inc. is Grid #625 of 837 in the Healthcare sector in United States, and Grid #3,132 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Cardiff Oncology, Inc. | 37.19 | 24 | 44 | 28 | 50 | 40 |
| Nutriband Inc. | 46.10 | 5 | 61 | 72 | 45 | 48 |
| LENSAR, Inc. | 48.65 | 34 | 40 | 39 | 76 | 54 |
| Citius Oncology, Inc. | 41.57 | 29 | 62 | 41 | 31 | 45 |
| Telomir Pharmaceuticals, Inc. | 39.98 | 4 | 58 | 55 | 40 | 43 |
| MAIA Biotechnology, Inc. | 48.24 | 20 | 76 | 34 | 51 | 60 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.50 |
| P/B ratio | 2.64 |
EEarnings
| Trailing EPS | ₹-56.83 |
| Forward EPS | ₹-50.67 |
NNitro
| Price | 85.35 |
| 52-week high | 313.51 |
| 52-week low | 71.98 |
| Fall from 52-week high | 72.8% |
TTorque
| Return on equity (ROE) | -94.08% |
| Debt-to-equity | 0.02 |
AAnchor
| Beta (price swings) | 1.42 |
| Market cap | ₹663 Cr |
| Insider holding | 6.20% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Cardiff Oncology, Inc.'s PosiPenta score?
Cardiff Oncology, Inc.'s PosiPenta is 37.19 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Cardiff Oncology, Inc. stand on the Penta Grid?
On the Penta Grid this week, Cardiff Oncology, Inc. is Grid #625 of 837 in the Healthcare sector in United States, and Grid #3,132 of 4,000 in United States.
Which PosiPenta pillar is strongest for Cardiff Oncology, Inc.?
Torque (durability), with a score of 50 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Cardiff Oncology, Inc.?
Price (valuation), with a score of 24 out of 100: weaker than most similar companies.
Has Cardiff Oncology, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.35 points, from 33.84 to 37.19.
PositoAI is for research and education only and is not investment advice.